VCVidyanath Chaudhary

Vidyanath Chaudhary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vidyanath Chaudhary has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dysregulation of mechanosensing signaling in monocytes of patients with systemic sclerosis is associated with skin inflammation

    by Vidyanath Chaudhary, Yong Du, Bikash Mishra, Marie Dominique Ah Kioon, Palak Ahuja, Lionel B. Ivashkiv, Marie-Elise Truchetet, Robert F. Spiera, Kimberly Lakin, Jessica K. Gordon, et al.

    Systemic sclerosis (SSc) is a severe autoimmune connective tissue disease characterized by immune dysregulation and progressive fibrosis of the skin and internal organs, resulting in substantial organ dysfunction and increased mortality. Fibrosis is driven in part by infiltration of immune cells, including monocytes that become activated within fibrotic tissue. However, how the mechanical properties of fibrotic skin regulate their function remains poorly understood. Here, we demonstrate that increased stiffness activates human monocytes through mechanosensing. Reanalysis of single cell RNA sequencing datasets revealed that skin infiltrating monocytes exhibit heightened inflammatory signatures as compared to circulating counterparts, with further amplification in SSc. Using collagen-coated hydrogels modeling physiological and fibrotic stiffness, we show that increased stiffness enhances CD86 expression, and broadly upregulates inflammatory transcriptional programs in human monocytes. Mechanistically, stiffness-driven activation was associated with chromatin remodeling and epigenetic reprogramming, identifying the transcription factor Specificity Protein 1 (SP1) as a central regulator. CRISPR–Cas9-mediated disruption or pharmacologic inhibition of SP1 significantly attenuated stiffness- induced inflammatory gene expression, whereas we found no evidence for involvement of the canonical YAP/TAZ–TEAD axis, and pharmacological modulation of PIEZO1 neither reproduced nor blocked the response. Further, monocytes from patients with SSc displayed altered transcriptional trajectories and an exaggerated inflammatory response to high stiffness, accompanied by reduced expression of wound healing and antifibrotic programs. Together, these findings identify SP1-dependent mechanosensing as a previously unrecognized pathway controlling human monocyte activation in the skin and provide mechanistic insight into how tissue stiffness sustains inflammation in SSc.

  • Mechanosensing regulates pDC activation in the skin through NRF2 activation

    by Vidyanath Chaudhary, Bikash Mishra, Marie Dominique Ah Kioon, Yong Du, Lionel B. Ivashkiv, Mary K. Crow, Franck J. Barrat

    Plasmacytoid DCs (pDCs) infiltrate the skin, chronically produce type I interferon (IFN-I), and promote skin lesions and fibrosis in autoimmune patients. However, what controls their activation in the skin is unknown. Here, we report that increased stiffness inhibits the production of IFN-I by pDCs. Mechanistically, mechanosensing activates stress pathways including NRF2, which induces the pentose phosphate pathway and reduces pyruvate levels, a product necessary for pDC responses. Modulating NRF2 activity in vivo controlled the pDC response, leading to resolution or chronic induction of IFN-I in the skin. In systemic sclerosis (SSc) patients, although NRF2 was induced in skin-infiltrating pDCs, as compared with blood pDCs, the IFN response was maintained. We observed that CXCL4, a profibrotic chemokine elevated in fibrotic skin, was able to overcome stiffness-mediated IFN-I inhibition, allowing chronic IFN-I responses by pDCs in the skin. Hence, these data identify a novel regulatory mechanism exerted by the skin microenvironment and identify points of dysregulation of this mechanism in patients with skin inflammation and fibrosis.


  • Open Access

    Data from Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer

    by Chang-Suk Chae, Tito A. Sandoval, Sung-Min Hwang, Eun Sil Park, Paolo Giovanelli, Deepika Awasthi, Camilla Salvagno, Alexander Emmanuelli, Chen Tan, Vidyanath Chaudhary, et al.

    Lysophosphatidic acid (LPA) is a bioactive lipid enriched in the tumor microenvironment of immunosuppressive malignancies such as ovarian cancer. Although LPA enhances the tumorigenic attributes of cancer cells, the immunomodulatory activity of this phospholipid messenger remains largely unexplored. Here, we report that LPA operates as a negative regulator of type I interferon (IFN) responses in ovarian cancer. Ablation of the LPA-generating enzyme autotaxin (ATX) in ovarian cancer cells reprogrammed the tumor immune microenvironment, extended host survival, and improved the effects of therapies that elicit protective responses driven by type I IFN. Mechanistically, LPA sensing by dendritic cells triggered PGE2 biosynthesis that suppressed type I IFN signaling via autocrine EP4 engagement. Moreover, we identified an LPA-controlled, immune-derived gene signature associated with poor responses to combined PARP inhibition and PD-1 blockade in patients with ovarian cancer. Controlling LPA production or sensing in tumors may therefore be useful to improve cancer immunotherapies that rely on robust induction of type I IFN.Significance:This study uncovers that ATX–LPA is a central immunosuppressive pathway in the ovarian tumor microenvironment. Ablating this axis sensitizes ovarian cancer hosts to various immunotherapies by unleashing protective type I IFN responses. Understanding the immunoregulatory programs induced by LPA could lead to new biomarkers predicting resistance to immunotherapy in patients with cancer.See related commentary by Conejo-Garcia and Curiel, p. 1841.This article is highlighted in the In This Issue feature, p. 1825

  • Open Access

    Chronic activation of pDCs in autoimmunity is linked to dysregulated ER stress and metabolic responses

    by Vidyanath Chaudhary, Marie Dominique Ah Kioon, Sung-Min Hwang, Bikash Mishra, Kimberly Lakin, Kyriakos A. Kirou, Jeffrey Zhang-Sun, R. Luke Wiseman, Robert F. Spiera, Mary K. Crow, et al.

    Plasmacytoid dendritic cells (pDCs) chronically produce type I interferon (IFN-I) in autoimmune diseases, including systemic sclerosis (SSc) and systemic lupus erythematosus (SLE). We report that the IRE1α-XBP1 branch of the unfolded protein response (UPR) inhibits IFN-α production by TLR7- or TLR9-activated pDCs. In SSc patients, UPR gene expression was reduced in pDCs, which inversely correlated with IFN-I–stimulated gene expression. CXCL4, a chemokine highly secreted in SSc patients, downregulated IRE1α-XBP1–controlled genes and promoted IFN-α production by pDCs. Mechanistically, IRE1α-XBP1 activation rewired glycolysis to serine biosynthesis by inducing phosphoglycerate dehydrogenase (PHGDH) expression. This process reduced pyruvate access to the tricarboxylic acid (TCA) cycle and blunted mitochondrial ATP generation, which are essential for pDC IFN-I responses. Notably, PHGDH expression was reduced in pDCs from patients with SSc and SLE, and pharmacological blockade of TCA cycle reactions inhibited IFN-I responses in pDCs from these patients. Hence, modulating the IRE1α-XBP1–PHGDH axis may represent a hitherto unexplored strategy for alleviating chronic pDC activation in autoimmune disorders.


  • Open Access

    Chemokines form nanoparticles with DNA and can superinduce TLR-driven immune inflammation

    by Yong Du, Marie Dominique Ah Kioon, Paoline Laurent, Vidyanath Chaudhary, Michael Pierides, Chao Yang, David Oliver, Lionel B. Ivashkiv, Franck J. Barrat

    Chemokines control the migratory patterns and positioning of immune cells to organize immune responses to pathogens. However, many chemokines have been associated with systemic autoimmune diseases that have chronic IFN signatures. We report that a series of chemokines, including CXCL4, CXCL10, CXCL12, and CCL5, can superinduce type I IFN (IFN-I) by TLR9-activated plasmacytoid DCs (pDCs), independently of their respective known chemokine receptors. Mechanistically, we show that chemokines such as CXCL4 mediate transcriptional and epigenetic changes in pDCs, mostly targeted to the IFN-I pathways. We describe that chemokines physically interact with DNA to form nanoparticles that promote clathrin-mediated cellular uptake and delivery of DNA in the early endosomes of pDCs. Using two separate mouse models of skin inflammation, we observed the presence of CXCL4 associated with DNA in vivo. These data reveal a noncanonical role for chemokines to serve as nucleic acid delivery vectors to modulate TLR signaling, with implications for the chronic presence of IFN-I by pDCs in autoimmune diseases.


  • Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16

    by Pei-Hui Wang, Zi-Wei Ye, Jian-Jun Deng, Kam-Leung Siu, Wei-Wei Gao, Vidyanath Chaudhary, Yun Cheng, Sin-Yee Fung, Kit-San Yuen, Ting-Hin Ho, et al.

    Mouse p202 is a disease locus for lupus and a dominant‐negative inhibitor of AIM2 inflammasome activation. A human homolog of p202 has not been identified so far. Here, we report a novel transcript isoform of human IFI16‐designated IFI16‐β, which has a domain architecture similar to that of mouse p202. Like p202, IFI16‐β contains two HIN domains, but lacks the pyrin domain. IFI16‐β is ubiquitously expressed in various human tissues and cells. Its mRNA levels are also elevated in leukocytes of patients with lupus, virus‐infected cells, and cells treated with interferon‐β or phorbol ester. IFI16‐β co‐localizes with AIM2 in the cytoplasm, whereas IFI16‐α is predominantly found in the nucleus. IFI16‐β interacts with AIM2 to impede the formation of a functional AIM2‐ASC complex. In addition, IFI16‐β sequesters cytoplasmic dsDNA and renders it unavailable for AIM2 sensing. Enforced expression of IFI16‐β inhibits the activation of AIM2 inflammasome, whereas knockdown of IFI16‐β augments interleukin‐1β secretion triggered by dsDNA but not dsRNA. Thus, cytoplasm‐localized IFI16‐β is functionally equivalent to mouse p202 that exerts an inhibitory effect on AIM2 inflammasome. Synopsis IFI16‐β, a novel transcript isoform of IFI16 is a functional homolog of mouse p202 and inhibits the AIM2 inflammasome. IFI16‐β impedes AIM2‐ASC complex formation and blocks cytoplasmic dsDNA sensing of AIM2. IFI16‐β shows a similar domain architecture than mouse p202. IFI16‐β associates with STING and is a weak inducer of type I interferons. IFI16‐β inhibits AIM2 inflammasome activation, and blocks its binding to cytoplasmic dsDNA.